Fundamental Analysis of NEUMORA THERAPEUTICS INC(NASDAQ:NMRA) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to NMRA. NMRA was compared to 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for NMRA as it has an excellent financial health rating, but there are worries on the profitability. NMRA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NMRA has reported negative net income.

NMRA had a negative operating cash flow in the past year.

NMRA had negative earnings in each of the past 5 years.

NMRA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NMRA has a worse Return On Assets (-83.31%) than 72.28% of its industry peers.

NMRA has a Return On Equity (-91.57%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-83.31%
ROE	-91.57%
ROIC	N/A

ROA(3y)-44.51%

ROA(5y)N/A

ROE(3y)-47.31%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NMRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for NMRA has been increased compared to 1 year ago.

NMRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

NMRA has an Altman-Z score of 2.76. This is not the best score and indicates that NMRA is in the grey zone with still only limited risk for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 2.76, NMRA is in the better half of the industry, outperforming 71.74% of the companies in the same industry.

There is no outstanding debt for NMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.76

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

NMRA has a Current Ratio of 10.98. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of NMRA (10.98) is better than 84.24% of its industry peers.

NMRA has a Quick Ratio of 10.98. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.

NMRA's Quick ratio of 10.98 is amongst the best of the industry. NMRA outperforms 84.24% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	10.98
Quick Ratio	10.98

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

NMRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.80%.

EPS 1Y (TTM)-4.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.53%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

NMRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.22% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y7.92%

EPS Next 2Y2.38%

EPS Next 3Y0.48%

EPS Next 5Y14.22%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NMRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NMRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y2.38%

EPS Next 3Y0.48%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NMRA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (1/6/2025, 8:00:01 PM)

Premarket: 2.49 +0.01 (+0.4%)

2.48

+0.31 (+14.29%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Inst Owners60.52%

Inst Owner Change0%

Ins Owners5.91%

Ins Owner Change-1.1%

Market Cap400.67M

Analysts85.33

Price Target24.1 (871.77%)

Short Float %9.4%

Short Ratio10.09

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-5.39%

Min EPS beat(2)-13.12%

Max EPS beat(2)2.34%

EPS beat(4)2

Avg EPS beat(4)-8.7%

Min EPS beat(4)-26.56%

Max EPS beat(4)2.53%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-1.56%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-12.76%

EPS NY rev (1m)0%

EPS NY rev (3m)-7.96%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.25
P/tB	1.25
EV/EBITDA	N/A

EPS(TTM)-1.87

EYN/A

EPS(NY)-1.7

Fwd EYN/A

FCF(TTM)-1.17

FCFYN/A

OCF(TTM)-1.14

OCFYN/A

SpS0

BVpS1.99

TBVpS1.99

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-83.31%
ROE	-91.57%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-44.51%

ROA(5y)N/A

ROE(3y)-47.31%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	845.16%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	10.98
Quick Ratio	10.98
Altman-Z	2.76

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)1048.77%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-4.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.53%

EPS Next Y7.92%

EPS Next 2Y2.38%

EPS Next 3Y0.48%

EPS Next 5Y14.22%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y3.96%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-44.29%

EBIT Next 3Y-10.81%

EBIT Next 5Y20.11%

FCF growth 1Y-30.82%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-42.1%

OCF growth 3YN/A

OCF growth 5YN/A

NEUMORA THERAPEUTICS INC (NMRA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens